Show simple item record

dc.contributor.authorBermejo Martín, Jesús Francisco
dc.contributor.authorKelvin, David J.
dc.contributor.authorEiros Bouza, José María 
dc.contributor.authorCastrodeza Sanz, José Javier 
dc.contributor.authorOrtiz de Lejarazu Leonardo, Raúl 
dc.date.accessioned2015-10-01T08:24:00Z
dc.date.available2015-10-01T08:24:00Z
dc.date.issued2009
dc.identifier.citationJournal of Infection Developing Countries 2009; 3(3):159-161.es
dc.identifier.issn1972-2680es
dc.identifier.urihttp://uvadoc.uva.es/handle/10324/13854
dc.descriptionProducción Científicaes
dc.description.abstractThe current outburst of a new H1N1 swine influenza strain(s) in México and the United States is causing great concern in health authorities and in the general population [1]. With the World Health Organization (WHO) reporting the pandemic potential of the new strain, it is necessary to determine which therapeutic options are available until a specific vaccine is available. Based on information from the Centre for Disease Control (CDC), the virus is sensitive to oseltamivir and zanamivir. Antivirals are strongly affected by viral mutations; thus their efficiency could be lost as the virus changes.es
dc.format.mimetypeapplication/pdfes
dc.language.isoenges
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectGripe - Vacunases
dc.titleMacroloides for the treatment of severe respiratory illness caused by novel H1N1 swine influenza viral strainses
dc.typeinfo:eu-repo/semantics/articlees
dc.identifier.doi10.3855/jidc.18es
dc.identifier.publicationfirstpage159es
dc.identifier.publicationissue3es
dc.identifier.publicationlastpage161es
dc.identifier.publicationtitleJournal of Infection in Developing Countrieses
dc.identifier.publicationvolume3es
dc.peerreviewedSIes
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record